Drug-induced parkinsonism: Cinnarizine and flunarizine are potent uncouplers of the vacuolar H+-ATPase in catecholamine storage vesicles

Neuropharmacology

Volumn 38, Issue 6, 1999, Pages 879-882

  Terland, Ole ^a   Flatmark, Torgeir ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

Calcium antagonist; Chromaffin granule ghosts; Cinnarizine; Dopamine; Parkinson's disease; Vacuolar H+ ATPase

Indexed keywords

ADENOSINE TRIPHOSPHATASE; BOVINE SERUM ALBUMIN; CINNARIZINE; FLUNARIZINE; MEMBRANE PROTEIN;

ADRENAL MEDULLA; ANIMAL CELL; ARTICLE; CATTLE; CHROMAFFIN GRANULE; CONTROLLED STUDY; DOPAMINE UPTAKE; IN VITRO STUDY; MODEL; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL;

ANIMALS; CATTLE; CHROMAFFIN CELLS; CINNARIZINE; DOPAMINE; ENERGY METABOLISM; FLUNARIZINE; PARKINSON DISEASE, SECONDARY; PROTON-TRANSLOCATING ATPASES; SYNAPTIC VESICLES; UNCOUPLING AGENTS; VACUOLES;

EID: 0032943159     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(98)00233-0     Document Type: Article

References (27)

1. Baquero M., Dominguez Sanz F.J., Burguera J.A., Cruz Campos G.A., Munoz R. Parkinsonismos de novo en ambito extrahospitalario (new forms of parkinsonism in hospice care). Rev. Neurol. 23:1995;964-968.
2. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
3. 2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study. J. Cereb. Blood Flow Metab. 15:1995;513-518.
4. Castaneda-Hernandez G., Hoyo-Vadillo C., Herrera J.E., Salazar L.A., Ortiz C., Hong E. Accumulation of cinnarizine, a calcium entry blocker, following usual dosage regimens. Proc. West. Pharmacol. Soc. 34:1991;421-424.
5. Castaneda-Hernandez G., Vargas-Alvarado Y., Aguirre F., Flores-Murrieta F.J. Pharmacokinetics of cinnarizine after single and multiple dosing in healthy volunteers. Arzneim.-Forsch./Drug Res. 43:1993;539-542.
6. Clough C.G. Parkinson's disease: management. Lancet. 337:1991;1324-1327.
7. Flatmark T., Grønberg M., Husebye E., Berge S.V. Inhibition by N-ethylmaleimide of the MgATP-driven proton pump of the chromaffin granules. FEBS Lett. 149:1982;71-74.
8. Gaggi R., Gianni A.M. Effects of calcium antagonists on biogenic amines in discrete brain areas. Eur. J. Pharmacol. 181:1990;187-197.
9. Garcia-Ruiz P.J., Yebenes J.G., Jimenez-Jimenez F.J., Vazquez A., Urra D.G., Morales B. Parkinsonism associated with calcium channel blockers: a prospective follow-up study. Clin. Neuropharmacol. 15:1992a;19-26.
10. Garzia-Ruiz P.J., Mena M.A., Penafiel N., Yebenes J.G. Cinnarizine-induced parkinsonism in primates. Clin. Neuropharmacol. 15:1992b;152-154.
11. 2+-dependent ATPase in bovine adrenal chromaffin granules. With special reference to the effect of inhibitors and energy coupling. Eur. J. Biochem. 164:1987;1-8.
12. Grønberg M., Terland O., Husebye E.S., Flatmark T. The effect of prenylamine and organic nitrates on the bioenergetics of bovine catecholamine storage vesicles. Biochem. Pharmacol. 40:1990;351-355.
13. Johnson R.G. Accumulation of biological amines into chromaffin granules: a model for hormone and neurotransmitter transport. Physiol. Rev. 68:1988;232-307.
14. Mena M.A., Yebenes M.J.G., Tabernero C., Casarejos M.J., Pardo B., Yebenes J.G. Effects of calcium antagonists on the dopamine system. Clin. Neuropharmacol. 18:1995;410-426.
15. Negrotti A., Calzetti S., Sasso E. Calcium-entry blockers-induced parkinsonism: possible role of inherited susceptibility. NeuroToxicology. 13:1992;261-264.
16. Norman P.T., Flatmark T. Increase in mitochondrial content of long-chain acyl-CoA in brown adipose tissue during cold-acclimation. Biochim. Biophys. Acta. 794:1984;225-233.
17. Okimoto K., Rajewski R.A., Uekama K., Jona J.A., Stella V.J. The interaction of charged and uncharged drugs with neutral (HP-β-CD) and anionically charged (SBE7-β-CD) β-cyclodextrins. Pharm. Res. 13:1996;256-264.
18. Peter D., Jimenez J., Liu Y., Kim J., Edwards R.H. The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors. J. Biol. Chem. 26:1994;7231-7237.
19. Rascol O., Clanet M., Montastruc J.L. Calcium antagonists and the vestibular system: a critical review of flunarizine as an antivertigo drug. Fundam. Clin. Pharmacol. 3:1989;79s-87s.
20. Terland O., Flatmark T. Oxidoreductase activities of chromaffin granule ghosts isolated from the bovine adrenal medulla. Biochim. Biophys. Acta. 597:1980;318-330.
21. +-ATPase and bioenergetics of catecholamine storage vesicles. Eur. J. Pharmacol. 207:1991;37-41.
22. Terland O., Flatmark T., Tangerås A., Grønberg M. Dopamine oxidation generates an oxidative stress mediated by dopamine semiquinone and unrelated to reactive oxygen species. J. Mol. Cell. Cardiol. 29:1997;1731-1738.
23. Todd P.A., Benfield P. Flunarizine. A reappraisal of its pharmacological properties and therapeutic use in neurological disorders. Drugs. 38:1989;481-499.
24. 3H]tyramine. Neurochem. Res. 18:1993;1125-1130.
25. Veitch K., Hue L. Flunarizine and cinnarizine inhibit mitochondrial complexes I and II: possible implication for parkinsonism. Mol. Pharmacol. 45:1994;158-163.
26. Vogelgesang R., Wood G., Peters T., Scheufler E. pH-dependent influence of membrane-incorporated flunarizine on Ca-binding to phosphatidylserine monolayer membranes. Biochem. Pharmacol. 37:1988;1597-1600.
27. Wilder-Smith C.H., Schimke J., Osterwalder B., Senn H.J. Cinnarizine for prevention of nausea and vomiting druing platin chemoterapy. Acta Oncol. 30:1991;731-734.